A HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model

Human epidermal growth factor receptor-2 (HER2) is upregulated in 20% to 30% of breast cancers and is a marker of a poor outcome. Due to the development of resistance to passive immunotherapy with Trastuzumab, active anti-HER2 vaccination strategies that could potentially trigger durable tumor-speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Nika, Lisa, Cuadrado-Castano, Sara, Asthagiri Arunkumar, Guha, Grünwald-Gruber, Clemens, McMahon, Meagan, Koczka, Krisztina, García-Sastre, Adolfo, Krammer, Florian, Grabherr, Reingard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631560/
https://www.ncbi.nlm.nih.gov/pubmed/31137559
http://dx.doi.org/10.3390/vaccines7020041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631560/
https://www.ncbi.nlm.nih.gov/pubmed/31137559
http://dx.doi.org/10.3390/vaccines7020041

Ejemplares similares